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ABSTRACT 
Background:  Many  chronic  diseases  and  illnesses  are  associated  with  one  or  more  chronic 
infections, dysfunction of mitochondria and reduced production of ATP.  This results in fatigue 
and other symptoms that occur in most if not all chronic conditions and diseases. 
 
Methods: This is a review of the published literature on chronic infections in neurodegenerative 
diseases  and  fatiguing  illnesses  that  are  also  typified  by  mitochondrial  dysfunction.    This 
contribution also reviews the use of natural supplements to enhance mitochondrial function and 
reduce the effects of chronic infections to improve overall function in various chronic illnesses. 
 
Results: Mitochondrial function can be enhanced by the use of various natural supplements, 
notably Lipid Replacement Therapy (LRT) using glyerolphospholipids and other mitochondrial 
supplements.    In  various  chronic  illnesses  that  are  characterized  by  the  presence  of  chronic 
infections, such as intracellular bacteria (Mycoplasma, Borrelia, Chlamydia and other infections) 
and viruses, LRT has proven useful in multiple clinical trials.  For example, in clinical studies on 
chronic fatigue syndrome, fibromyalgia syndrome and other chronic fatiguing illnesses where a 
large majority of patients have chronic infections, LRT significantly reduced fatigue by 35-43% 
in different clinical trials and increased mitochondrial function.  In clinical trials on patients with 
multiple intracellular bacterial infections and intractable fatigue LRT plus other mitochondrial 
supplements significantly decreased fatigue and improved mood and cognition. 
 
Conclusions:  LRT formulations designed to improve mitochondrial function appear to be useful 
as  non-toxic  dietary  supplements  for  reducing  fatigue  and  restoring  mitochondrial  and  other 
cellular membrane functions in patients with chronic illnesses and multiple chronic infections. 
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Background 
Patients with chronic neurodegenerative, neurobehavioral and fatiguing illnesses commonly test 
positive for systemic and central nervous system (CNS) bacterial and viral infections [1-3].  In 
addition, other chronic illnesses where neurological manifestations are routinely found, such as 
autoimmune diseases and other chronic illnesses and disorders, also show evidence of systemic 
bacterial and viral infections that could be important in disease inception, progression and/or 
enhancing the types and severities of signs and symptoms [2, 3].   
Evidence  of  bacterial  infections,  such  as  Mycoplasma  species,  Chlamydia  pneumoniae, 
Borrelia  burgdorferi,  among  others,  and  viruses,  such  as  human  herpesvirus  (HHV), 
cytomegalovirus (CMV), human herpes viruses (HHV) and other viral infections, have revealed 
high rates of infection in the illnesses listed above that were not found in control populations [1-
3].  Although the specific roles of chronic infections in various diseases and their pathogeneses 
have not been carefully determined, the data suggest that chronic bacterial and/or viral infections 
are common features of essentially all progressive chronic diseases [1-3]. 
Another  common  finding  in  chronic  illness  patients  is  mitochondrial  dysfunction, 
characterized by loss of efficiency in the electron transport chain, reductions in mitochondrial 
inner  membrane  trans-membrane  potential  and  reductions  in  the  synthesis  of  high-energy 
molecules such as ATP [4-6].  This is also a characteristic of aging, and it essentially occurs in 
all chronic diseases, including cancer [5-7]. 
This review will concentrate on commonly acquired mechanisms that affect mitochondrial 
function.  To treat functional loss associated wtih chronic infections mitochondrial replacement 
strategies with natural supplements and combinations of natural supplements have been used, 
including  vitamins,  minerals,  enzyme  cofactors,  antioxidants,  metabolites,  transporters, 
membrane-type phospholipids and other natural supplements in order to improve mitochondrial 
function. 
 
Introduction 
Chronic  infections  appear  to  be  a  common  feature  of  various  diseases,  including 
neurodegenerative, psychiatric, neurobehavioral diseases and other conditions [1-3, 8].  Chronic 
infections are also associated with autoimmune diseases [9, 10] and fatiguing illnesses [1, 3, 11].  
This will be discussed in various sections of this review.  In addition, many chronic illnesses are 
directly caused by chronic infections, such as Lyme disease, brucellosis, babesiosis, and other 
infection-based chronic diseases [2, 12-14]. 
Chronic infections collectively result in induction of excess Reactive Oxygen Species (ROS) 
and Reactive Nitrogen Species (RNS) that damage cellular structures, especially mitochondrial 
membranes [15-17].  Mitochondria are especially sensitive to excess levels of ROS/RNS, and in 
chronic illnesses there is extensive damage to mitochondria in the form of membrane oxidation, 
damage to mitochondrial DNA (mtDNA) and loss of mitochondrial enzymatic function and inner 
mitochondrial  membrane  potential  [6-8,  18-20].    In  this  review  we  will  discuss  the  use  of Functional Foods in Health and Disease 2014; 4(1):23-65                                                                    Page 25 of 65 
 
comprehensive approaches to restore mitochondrial function damaged by infections and other 
causes. 
Patients with chronic illnesses (often caused by or exacerbated by chronic infections) are 
particularly difficult to treat using single modality approaches, and this is particularly true for 
patients  who  have  multiple  chronic  infections  [21,  22].    The  multi-focal  nature  of  chronic 
diseases and the fact that often treatments are given to suppress adverse signs and symptoms, 
rather  than  treat  causes  of  the  disease  or  its  progression,  have  resulted  in  incomplete  or 
ineffective treatments.  On the other hand, even if the causes of chronic diseases are known, by 
the time therapeutic interventions are undertaken, it may be entirely too late to use approaches 
that might work on the disease at an early stage or if chronic infections were not also present.  At 
the stage(s) of disease when patients usually seek medical care for their conditions, they usually 
have  multiple  problems,  including  chronic  infections,  and  each  of  these  problems  usually 
requires complex therapeutic approaches.  Their multiple chronic infections also cause additional 
cellular damage [1, 2, 8].   
Multiple alternations in mitochondrial membranes, proteins and mtDNA are thought to be 
the cause for mitochondrial dysfunction, and this damage can also accumulate over time [6, 23].  
By the time patients seek care, they usually have multiple defects in their mitochondria, and thus 
there  are  no  simple  approaches  that  are  effective  in  promoting  functional  recovery  of  their 
mitochondria.  With this in mind, we have begun this review by discussing the evidence for 
chronic  infections  and  mitochondrial  dysfunction  in  selected  chronic  illnesses  and  diseases.  
Then we will discuss the role that various supplements play in restoring mitochondrial function, 
even  in  patients  with  multiple  chronic  infections  that  continue  to  degrade  mitochondrial 
components.  Finally  we  will  discuss  the  role  of  combination  supplements  for  restoring 
mitochondrial function in patients with chronic illnesses and multiple chronic infections.   
   
Neurodegenerative Diseases 
Neurodegenerative  diseases,  or  chronic  degenerative  diseases  of  the  central  nervous  system 
(CNS)  that  cause  dementia,  are  mainly  diseases  of  the  elderly  [1,  2].    On  the  other  hand, 
neurobehavioral  diseases  are  found  mainly  in  young  patients  and  include  autism  spectrum 
disorders  (ASD),  such  as  autism,  attention  deficit  disorder,  Asperger’s  syndrome  and  other 
disorders  [24].    For  the  most  part,  the  causes  of  these  neurological  diseases  remain  largely 
unknown but it is thought that multiple factors are involved in each disease [1, 2].
   
Neurodegenerative diseases are characterized by molecular and genetic changes in nerve 
cells that result in nerve cell dysfunction, degeneration and ultimately cell death, resulting in 
neurological signs and symptoms and eventually dementia [1, 2].  In contrast, neurobehavioral 
diseases  are  related  to  fetal  brain  and  early  post-partum  development  but  are  less  well 
characterized at the cellular level.  Both of these disease types involve genetic and environmental 
factors [24, 25], and they also have multiple chronic infections [1-3, 26, 27].  Even less well 
characterized  at  the  cellular  and  genetic  level  are  the  psychiatric  disorders,  such  as 
schizophrenia, paranoia, bipolar disorders, depression and obsessive-compulsive disorders, but 
these diseases are also associated with the presence of chronic infections [3]. 
Genetic alternations have been found in neurodegenerative and neurobehavioral diseases, 
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and usually not directly related to simple gene alterations, such as single mutations and deletions, 
that lead to single protein molecule alterations [24, 25, 28].  Importantly, mutations that affect 
mitochondrial function are known to be associated with neurodegenerative and neurobehavioral 
diseases [29, 30].  These include mutations in mtDNA as well as nuclear DNA [29].  In addition 
to  chronic  infections  and  genetic  changes,  environmental  toxins,  heavy  metals,  nutritional 
deficiencies,  autoimmune  immunological  responses,  vascular  diseases,  head  trauma  (and 
accumulation of fluid in the brain), changes in neurotransmitter concentrations, among other 
elements,  are  thought  to  be  collectively  involved  in  the  pathogenesis  of  various 
neurodegenerative and neurobehavioral diseases [1, 2, 24-31].  These important topics will not 
be discussed in detail in this review. 
Chronic Infections are important factors in neurodegenerative and neurobehavioral diseases, 
and infectious agents may enter the brain within infected migratory macrophages.  Alternatively, 
they  can  also  gain  access  by  direct  penetration  of  the  blood-brain-barrier  or  entry  by 
intraneuronal transfer from peripheral nerves [32].  Cell wall-deficient bacteria, such as species 
of  Mycoplasma,  Chlamydia  (Chlamydophila),  Borrelia,  Brucella,  among  others  and  various 
viruses are candidate brain infectious agents, because they are capable of CNS penetration and 
have been found routinely in neurodegenerative and neurobehavioral diseases [1-3, 26, 27, 32, 
33].  Such infections are usually systemic and can affect immune systems and essentially any 
organ system, resulting in a variety of systemic signs and symptoms that are not limited to the 
CNS [10, 11, 26, 27, 32, 33]. 
   
Amyotrophic lateral sclerosis (ALS) 
ALS is an adult-onset, progressive neurodegenerative disease of unknown etiology that affects 
both central and peripheral motor neurons where patients show gradual progressive weakness 
and paralysis of muscles due to destruction of upper motor neurons in the motor cortex and lower 
motor neurons in the brain stem and spinal cord [34, 35].  Eventually this results in death, usually 
by respiratory failure [35]. 
Chronic infections in ALS, such as the finding of enterovirus sequences in a majority of 
ALS spinal cord samples by polymerase chain reaction (PCR) [36], have attracted widespread 
attention.    However,  others  have  failed  to  detect  enterovirus  sequences  in  ALS  spinal  cord 
samples [37]. Using PCR methods systemic mycoplasmal infections have been found in a high 
percentage  (83%)  of  ALS  patients  [38].    For  example,  all  of  the  tested  Gulf  War  veterans 
diagnosed with ALS from three nations had systemic mycoplasmal infections [38].  In addition, a 
majority of ALS patients  in  Lyme endemic areas  show immunological evidence of Borrelia 
infections  [39],  and  some  patients  diagnosed  with  ALS  were  subsequently  found  to  have 
neuroborreliosis infections [40].  Although high rates of infection may occur in certain regions, 
the  overall  rate  of  Borrelia  infections  in  ALS  is  low  (10%  or  less)  in  North  America  [41].  
MacDonald [42], however, observed a high incidence of spirochetal forms in the brain tissues of 
ALS patients and in patients with other neurodegenerative diseases, suggesting that the presence 
of chronic bacterial infections in the CNS of neurodegenerative diseases patients is much more 
common than previously assumed.  
ALS patients also show evidence of other infections.  These include: human herpes virus-6 
(HHV-6),  Chlamydia  pneumoniae,  cyanobacteria  and  other  infections  [43-45].    Chronic Functional Foods in Health and Disease 2014; 4(1):23-65                                                                    Page 27 of 65 
 
infections plus other defects (accumulation of glutamate causing excitotoxicity, deficiency of 
nerve  growth  factor,  autoimmune  reactions  against  motor  neurons  and  dysfunction  of 
mitochondrial superoxide dismutase) have been proposed to be important in ALS pathogenesis 
[review: 2]. 
 Mitochondrial dysfunction is a common feature of ALS and animal models of ALS [46, 
47].  Evidence from patients with sporadic and familial ALS and from ALS models based on the 
over-expression  of  mutant  SOD1  found  in  a  small  subset  of  patients,  clearly  point  to 
mitochondrial damage as a relevant facet of this neurodegenerative condition [46].  In addition to 
mutations  in  superoxide  dismutase  genes,  some  ALS  patients  present  with  mutations  in 
mitochondrial  transport  genes  and  misfolding  in  inclusion  proteins,  ubiquilin-2  and  other 
mitochondrial  associated  proteins  [review:  47].    Dysfunction  in  several  other  cellular 
mechanisms,  including  mitophagy,  oxidative  stress,  lipid  peroxidation  and  cholesterol 
esterification, protein and neurofilament aggregation, impaired axonal transport, among other 
changes in ALS patients have been reviewed recently [47, 48]. 
 
Multiple Sclerosis (MS) 
The most common demyelinating neurological disease is MS [49].  MS can occur in all age 
groups  as  a  cyclic  (relapsing-remitting)  or  a  progressive  disease  that  continues  progressing 
without remitting [49].  Inflammation and the presence of autoimmune antibodies against myelin 
and  other  nerve  cell  antigens  are  thought  to  cause  myelin  sheath  breakdown,  resulting  in 
decrease or loss of electrical impulses along nerve fibers [49, 50].  In the MS patients with 
progressive neurological symptoms damage occurs additionally by the deposition of plaques on 
nerve cells to the point where nerve cell death occurs.  Importantly, breakdown of the blood-
brain  barrier  in  the  CNS  of  MS  patients  is  associated  with  local  inflammation  caused  by 
activated glial cells [49, 50].  The combination of demyelinization, plaque damage and blood-
brain barrier disruption causes multiple, variable symptoms, but they usually include impaired 
vision,  alterations  in  motor,  sensory  and  coordination  nerve  systems  along  with  cognitive 
dysfunction [50]. 
MS is a disease in which environmental, genetic and epigenetic factors determine the risk of 
developing MS, its progression and responsiveness to treatment [51, 52].  Just as in ALS, there 
are multiple genetic components in MS [51, 53].  Although it has been established that there is a 
genetic basis to MS susceptibility, epidemiological and twin studies suggest that MS is basically 
an acquired disease with some genetic and environmental components [54]. 
The molecular mechanisms through which environmental signals are translated into changes 
in gene expression include: DNA methylation, post-translational modification of nucleosomal 
histones, and non-coding RNAs.  These mechanisms are regulated by families of specialized 
enzymes that are tissue-selective and cell-type specific [54]. 
Chronic infections have been linked to the pathophysiology of MS [55, 56].  For example, 
MS patients show immunological and cytokine elevations consistent with chronic infections [57, 
58].  An infectious basis for MS has been under examination for some time, and patients have 
been tested for various viral and bacterial infections [1, 3, 53, 55, 56].   
One of the most consistent findings in MS patients has been the presence of C. pneumoniae 
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progressive MS patients for the presence of C. pneumoniae in cerebrospinal fluid by culture, 
PCR and immunoglobulin reactivity Sriram et al. [60] were able to identify C. pneumoniae in 
64% of MS cerebrospinal fluid versus 11% of patients with other neurological diseases.  They 
also found high rates of PCR-positive MOMP gene (97%) in MS- patients (versus 18% in other 
neurological diseases), and this correlated with a high rate of patients being serology-positive 
(86%) for Chlamydia antigens by ELISA and Western blot analysis [60]. MS patients examined 
for oligoclonal antibodies against C. pneumoniae revealed that 82% of MS patients were positive 
compared to none of the control non-MS neurological patients [61].  Similarly, C. pneumoniae 
RNA and DNA transcripts were found in mononuclear cells and cerebrospinal fluids of 64.2% of 
MS patients but in only 3 controls [62].  
The brain tissues of MS and non-MS neurological patients have also been examined for C. 
pneumoniae antigens  [63].  Using immunohistochemistry to  find  C. pneumoniae  antigens  in 
formalin-fixed  brain  tissue  Sriram  et  al.  [63]  found  that  in  a  subset  of  MS  patients  (35%) 
Chlamydial antigens were localized to ependymal surfaces and pariventricular regions.  Positive 
reactions  were  not  found  in  brain  tissue  samples  from  other  neurological  diseases.    PCR 
amplification of C. pneumoniae genes was accomplished in 63% of brain tissue samples from 
MS patients but none in frozen brain tissues from other neurological diseases.  In addition, using 
immuno-electron  microscopy  the  sediment  from  cerebrospinal  fluid  was  examined  for 
Chlamydial antigens [63].  Sriram et al. [63] found that the electron dense bodies resembling 
bacterial structures  that were positive by immuno-electron microscopy  correlated with  tissue 
PCR-positive MS cases (91% positive using both methods).   
Using different nested PCR methods to examine additional C. pneumoniae gene sequences 
in the cerebrospinal fluid of 72 MS patients Contini et al. [64] were able to match these results to 
MS-associated lesions seen by MRI.  Grimaldi et al.
 also used MRI to link the presence of C. 
pneumoniae infection with abnormal MRI results and found linkage in 21% in MS patients [65].  
The MS patients with C. pneumoniae infections were also the MS patients with more progressive 
disease.  Indeed, higher rates of C. pneumoniae transcription were found in the cerebrospinal 
fluid of 84 patients with the more progressive form of MS [66].  These studies strongly support 
the presence of C. pneumoniae in the brains of MS patients with progressive disease [67, 68].  
Not all researchers have found C. pneumoniae
 or other bacteria
 in the brains of MS patients 
[69, 70].  For example, Hammerschlag et al. used nested PCR and culture to examine frozen 
brain  samples  from  MS  patients  but  could  not  find  any  evidence  for  C.  pneumoniae  gene 
sequences [71].  Thus the evidence linking C. pneumoniae infection with MS is not universally 
accepted,  and  other  genetic  changes  may  be  necessary  to  complete  the  link  between  such 
infections and the etiology of MS [72].  
 Multiple infections in MS patients may complicate the evidence linking MS with specific 
chronic infections.  Thus other infections similar to C. pneumoniae could be involved rather than 
just one specific infection [1].   In addition  to  C. pneumoniae, MS patients  could  also  have 
Mycoplasma species, B. burgdorferi and other bacterial infections as well as viral infections [73].  
When multiple infections are considered, it is likely that >90% of MS patients have obligate 
intracellular bacterial infections. 
 
 Various viruses have also been found in MS patients.  For example, HHV-6 has been found 
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control samples [74].  PCR was used to examine postmortem brain tissue and controls for the 
presence of various neurotrophic viruses [74].  These studies revealed that 57% of MS cases and 
43% of non-MS neurological disease controls contain sequences for HHV-6, whereas 37%, 28%, 
and  43%,  respectively,  contained  sequences  for  herpes  simplex  virus  (HSV)-1  and  –2  and 
varicella zoster virus.  Although impressive, the data did not achieve statistical significance.  
They also found that 32% of the MS active plaques and 17% of the inactive plaque areas were 
positive for HHV-6 [74].   
Using sequence difference analysis Challoner et al. searched for pathogens in MS brain 
specimens and found that >70% of MS patients were positive for infection-associated sequences 
[76].  They also used immunocytochemistry and found positive staining around MS plaques 
more frequently than around surrounding white matter.  Additionally, HHV-6 DNA was found in 
peripheral leukocytes in the systemic circulation of MS patients [77] but not in every study [78]. 
 
 Examination of the literature strongly suggests an infectious process in MS [1, 55, 56, 79, 
80].  In most studies the more progressive forms of MS rather than the relapsing-remitting forms 
of MS were associated with chronic infections.  Thus chronic infections may play a role in 
progression of MS.  If infections like C. pneumoniae and Mycoplasma species are important in 
MS, then antibiotics effective against these infections should improve clinical status [1].  This 
has, in fact, been seen in most but not in all MS patients [81].
  As in other neurodegenerative 
diseases, multiple factors appear to be involved in the pathogenesis of MS [1, 49, 55, 56, 82].  
One of the factors in MS appears to be mitochondrial dysfunction due to oxidative injury 
[83, 84].  Broadwater et al. have identified several MS-related damaged mitochondrial proteins 
that  are  involved  in  respiration,  including  cytochrome  c  oxidase  subunit  5b,  an  isozyme  of 
appears to be damage to the permeability transition pore (PTP) by excess reactive oxygen species 
(ROS)  [86].    This  critical  structure  is  central  to  mitochondrial  dysfunction  by  allowing  ion 
dysregulation within neural cells that drives neurodegeneration by allowing the PTP to change 
the ion gradients inside mitochondria, lowering inner membrane trans-membrane potential (thus 
reducing  oxidative  phosphorylation  [87]),  promoting  matrix  expansion  leading  to  release  of 
cytochrome  c  and  initiating  cell  death  programs  [86].    In  addition,  the  energy  and  calcium 
balance  in  neurons  plays  an  important  role  in  maintaining  a  healthy  myelin  sheath,  and  a 
hallmark of MS is axon demyelation due to mitochondrial dysfunction [83], which drives an 
inflammatory response characteristic of MS progression [88]. 
 
Alzheimer’s disease (AD) 
AD is characterized by distinct pathological changes in brain cells and tissues [1, 2].  Among the 
most notable are the appearance of plaques and tangles of neurofibrils in brain nerve cells that 
affect synapses and nerve-nerve cell communication.  These alterations involve the deposition of 
altered amyloid proteins [89, 90].   Although the origins of AD are not known for certain, the 
formation of the amyloid plaques and neurofiber tangles found in AD may be due to genetic 
defects and resulting changes in the structure of beta amyloid proteins, which may be caused by 
chemicals or other toxic events, inflammatory responses, excess oxidative stress and increases in 
ROS, loss of nerve trophic factors and reductions in nerve cell transmission [89-92].
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Infections are potentially important in the AD disease process [93, 94].  One pathogen that 
has attracted considerable attention because of its neurotropism is C. pneumoniae [95, 96].  This 
intracellular bacterium has been found at high incidence in the brains of AD patients by PCR and 
immunohistochemistry [96].  C. pneumoniae has also been found localized in nerve cells in close 
proximity to neurofibrillary tangles, a characteristic of AD [96, 97].   
C. pneumoniae can invade endothelial cells and promote the transmigration of monocytes 
through human brain endothelial cells into the brain parenchyma [98].  C. pneumoniae has been 
found in the brains of most AD patients [95],
 and it has been cultured from the brain tissue of AD 
patients [99].  Immunohistological detection of C. pneumoniae was observed inside and outside 
cells in the frontal and temporal cortices of AD brains [100].  Indeed, in experiments with mice 
injection of C. pneumoniae stimulated brain beta amyloid plaque formation [101].  The data are 
compelling, but some investigators have not been able to duplicate the findings on infections in 
AD [102]. 
In addition to C. pneumoniae investigators have found other infections in AD patients, such 
as B. burgdorferi [103, 104].   Using serology, culture, Western blot and immunofluorenscence 
methods this infection has been examined in AD patients (with or without a diagnosis of Lyme 
disease) and found to be present [104, 105].  The presence of intracellular infections like B. 
burgdorferi in AD patients has been proposed to be a primary event in the formation of AD beta 
amyloid plaques, which are thought to occur by the formation of “congophilic cores” that attract 
beta amyloid materials [106].  In fact, exposure of glial and neuronal cells in vitro to Borrelia 
burgdorferi  spirochetes  and  to  the  inflammatory  bacterial  lipopolysaccharide  LPS  caused 
morphological changes analogous to those found in deposits in AD brains [107].  Also detected 
were  increases  in  beta  amyloid  precursor  protein  and  hyperphosphorylated  tau  protein 
characteristic of AD [107].  Several reports indicate that AD nerve cells are often positive for B. 
burgdorferi, indicating that this intracellular bacteria could be important in the pathogenesis of 
AD [103-106, 108].  However, there are reports that could not find evidence for the presence of 
Borrelia in AD brain tissue [109].   
Miklossy has reviewed the data indicating that chronic infections, including B. burgdorferi, 
are  commonly  found  in  AD  patients  and  has  concluded  that  intracellular  bacteria  contain 
amyloidogenic proteins that can induce amyloid beta deposition and tau phosphorylation [110, 
111].  In addition, specific bacterial ligands and bacterial and viral DNA and RNA increase the 
expression of proinflammatory molecules that activate the innate and adaptive immune systems.  
Evasion of brain pathogens from destruction by the host immune system can result in persistent 
infection, chronic inflammation, neuronal destruction and beta amyloid deposition [111].
 
The hypothesis that intracellular microorganisms or their protein products can induce beta 
amyloid protein and then provide “nucleation sites” for the attraction of beta amyloid materials is 
attractive  [111],  but  other  factors,  including  the  induction  of  reactive  oxygen  species,  lipid 
peroxidation and the breakdown of the lysosomal membranes releasing lysosomal hydrolases, 
are also thought to be important in beta amyloid deposition [108].  An infectious basis in AD 
pathogenesis is attractive; however, although some negative reports imply that infections like B. 
burgdorferi are not essential in AD pathogenesis [109].  On the other hand, other intracellular 
bacterial infections (Mycoplasma, Chlamyda, Helicobacter etc.) have been found in AD patients 
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been proposed that chronic infections may be important cofactors in AD and contribute to the 
pathogenic process [113]. 
Viral  infections  may  also  play  a  role  in  AD  pathogenesis.    Herpes  virus  infections, 
especially HSV-1, have been found in AD patients [114, 115].  Previously it was determined that 
HSV-1 but not a related neurotrophic virus (varicella zoster virus) was present more often in AD 
brains, and this could be linked to patients who have the AD risk factor ApoE e4 allele [116, 
117].    Similar  to  bacterial  proteins,  HSV-1  proteins  may  also  be  involved  in  the  abnormal 
aggregation of beta amyloid fragments within the AD brain, but in this case by reducing the 
amount  of  full-length  beta  amyloid  precursor  protein  and  increasing  the  amounts  of  their 
fragments [118].  HSV-1 infection of glial and neuronal cells resulted in a dramatic increase in 
the  intracellular  levels  of  beta  amyloid  forms,  whereas  the  levels  of  native  beta  amyloid 
precursor protein decreased [119].  This has been found in mice infected with HSV-1, indicating 
that HSV-1 is probably involved directly in the development of senile-associated plaques.  Other 
herpes viruses, such as HHV-6, have also been found in AD patients, but it is thought that this 
virus is not directly involved in AD pathogenesis.  Another virus that has been implicated in AD 
is cytomegalovirus [120].  A high proportion of brains from vascular dementia patients show 
evidence of both HSV-1 and cytomegalovirus [120].
 
Mitochondrial dysfunction may be an early event in the pathogenesis of AD [121-123]. AD 
patients  show  impairments  in  mitochondrial  function  that  start  early  in  process  of 
neurodegeneration [121, 123].  Mutations in the AbetaPP and tau genes induce oxidative stress 
and  mitochondrial  dysfunction  leading  eventually  to  apoptotic  cell  death  [124].    Indeed, 
transgenic  mouse  models  of  AD  point  to  impairments  in  oxidative  phosphorylation  as  an 
important aspect of AD pathogenesis [125].  The oxidative stress is thought to cause protein 
alterations that have synergistic effects on mitochondria, leading to synaptic dysfunction and 
apoptotic cell death [124]. 
 
Parkinson’s Disease (PD) 
PD  is  characterized  by  akinesia,  muscular  rigidity  and  tremor.    In  addition,  autonomic 
dysfunction, olfactory disturbances, depression, sensory and sleep disturbances and frequently 
dementia  characterize  this  disease  [126].    The  pathology  indicates  a  progressive  loss  of  the 
-
synuclein.  Extensive brain degeneration also occurs in PD [127].  Inclusion bodies and protein 
aggregations or defects in their degradation characteristically are characteristic of PD, but their 
role  in  PD  pathogenesis  is  unclear  [127,  128].    Available  evidence  suggests  a  relationship 
between PD and specific genetic changes, such as changes in the genes in mitochondria, those 
affecting protein degradation, organelle trafficking and vesicular fusion, and in proteins involved 
in oxidative stress or antioxidant function [129. 130].  Inflammation has also been associated 
with PD [131]. 
PD has been proposed to be due to neurotoxic events in genetically susceptible individuals 
that are especially sensitive to neuro-oxidative damage [132].  Multiple environmental factors 
and genetic background are also statistically related risk factors for PD [133].  The mitochondria 
in  neuromelanin-containing  dopaminergic  neurons  of  the  substantia  nigra  are  the  targets  for 
oxidative  damage  [128,  133,  134],  and  early  life  exposures  are  also  important  [135].    For Functional Foods in Health and Disease 2014; 4(1):23-65                                                                    Page 32 of 65 
 
example,
 early life exposure to brain injury, chemicals and/or infections may initiate a cyclic 
inflammatory process involving oxidative damage, excitotoxicity, mitochondrial dysfunction and 
altered proteolysis that later in life results in neuron death in the substantia nigra [136, 137]. 
Chronic infections have been proposed as important in PD pathogenesis [136, 137].  In fact, 
regression  analysis  of  a  case-control  study  on  infections  in  PD  patients  clearly  showed  that 
infectious processes are an important risk factor in PD [138].  One infection found in PD that has 
aroused  considerable  interest  is  the  presence  of  chronic  gastrointestinal  Helicobacter  pylori 
infections  [139].    Treatment  of  this  infection  in  PD  patients  offered  relief  from  late  stage 
cachexia  [140].    Helicobacter  pylori-infected  PD  patients  also  showed  reduced  L-dopa 
absorption and increased clinical disability [141], and in antimicrobial-treated PD patients there 
was increased L-dopa absorption and decreased clinical disability [142].  Although H. pylori 
may not be directly involved in the pathogenesis of PD, its systemic presence has been proposed 
to affect the progression and treatment of PD [141]. 
PD patients’ chronic infections have been linked to autoimmunity and inflammation  [143-
145], and the role of neuro-inflammatory and oxidative processes in nigral degeneration has 
gained  increasing  attention  [145,  146].      Moreover,  experimental  models  of  PD  have  been 
developed using viral or bacterial infections to initiate the pathogenic process [147, 148].  In 
examining  PD  patients  various  infections  have  been  found,  especially  bacterial  and  viral 
infections [144, 149].  For example, spirochetes have also been found in the brain Lewy bodies 
of  Lyme-associated  PD  patients  [150].    Other  infections,  such  as  viral  encephalitis  [151], 
cornavirus  [152],    Mycoplasma  pneumoniae  [153],  AIDS-associated  infections  of  the  basal 
ganglia [154], HIV [155], among other infections, have been found in PD patients [144, 149, 
155].  Additional research will be necessary to establish whether a causal link exists between PD 
and chronic infections [143, 155, 156]. 
A common link between oxidative stress, mitochondrial dysfunction and PD exists [157, 
158].  Although the underlying mechanisms for selective dopaminergic nerve degeneration in PD 
are not completely known, the increase in ROS in Parkinson’s substantia nigra neurons results in 
increased  DNA  mutation,  especially  in  mtDNA,  reduced  efficiency  of  the  electron  transport 
chain, and changes in protein aggregation and lipid oxidation that contribute to mitochondrial 
destruction (mitophagy) and neurodegeneration [132, 145, 156-158].   Mutations in genes that 
protect neural cells from oxidative damage-mediated mitochondrial dysfunction, such as tensin 
(PTEN)  homologue-induced  kinase-1  (PINK1),  are  known  to  be  associated  with  recessively 
inherited PD, and this also points to mitochondrial damage as an underlying defect in PD [159].  
PINK1 is involved in mitochondrial quality control, and under steady state conditions PINK1 is 
rapidly and constitutively degraded in a mitochondrial membrane potential-dependent manner 
[160].    Loss  of  mitochondrial  inner  membrane  potential  stabilizes  PINK1  mitochondrial 
accumulation and stimulates the initiation of autophagic degradation and removal of damaged 
mitochondria (mitophagy), but mutations in PINK1 inhibit this process [161].  This implicates 
loss of mitochondrial integrity and mitophagy in the pathogenesis of PD. 
  
Neurobehavioral Diseases 
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ASD  includes  autism,  Asperger’s  syndrome,  among  other  disorders.  These  diseases  affect 
primarily young patients who generally suffer from an inability to properly communicate, form 
relationships with others and respond appropriately to their environment.  ASD patients do not 
all  share  the  same  signs  and  symptoms  but  tend  to  have  in  common  certain  social, 
communication,  motor  and  sensory  problems  (non-compliance,  hyperactivity,  sensory 
defensiveness, self-injury, among others) that affect their behavior. They can display repetitive 
actions and develop troublesome fixations with specific objects, and they are often painfully 
sensitive to certain sounds, tastes and smells [162, 163]. 
Multiple factors appear to be involved in ASD, including genetic factors, environmental 
exposures, such as heavy metals and chemicals and biological exposures, which are probably 
different in each patient [27, 28, 164-169].  ASD patients appear to have similarities in genetic 
defects and environmental exposures that have been proposed to play interactive roles that are 
probably important in patient morbidity or in illness progression [170, 171]. 
 Chronic infections appear to be an important element in the development of ASD [2, 26, 27, 
168, 169].  In ASD patients more than 50 different bacterial, viral and fungal infections have 
been documented [27].   A few of these occur at high incident rates and may be more important 
than others in causing ASD symptoms [2, 169].  ASD patients also present with a number of 
nonspecific  chronic  signs  and  symptoms  that  suggest  infections,  such  as  fatigue,  headaches, 
gastrointestinal and vision problems as well as intermittent low-grade fevers and other signs and 
symptoms  [169,  172].    Increased  titers  to  various  viruses  as  well  as  bacterial  and  fungal 
infections have been commonly seen in ASD patients [27, 169, 172-174].  
Infections  along  with  environmental  exposures  to  chemicals  and  heavy  metals  is 
controversial but in some cases may be important in the development of ASD in genetically 
susceptible  children  [27,  28,166-174].    The  relationship  between  ASD  and  heavy  metals  is 
controveral but could be linked to the multiple vaccines given during pre-school years [166, 
167].  ASD often developes only after multiple childhood immunizations, and the sharp increase 
in Autism may be linked to vaccines after they came into widespread use [167].  Many of these 
vaccines  contain  mercury  and  other  toxic  preservatives,  and  some  may  also  contain 
contaminating bacteria, as found in 6% of veterinary vaccines [175].  ASD is also related to 
environmental infections, such as Lyme Borrelia and associated co-infections [21, 27, 169, 174]. 
An interesting study on the transmission of infections and subsequent ASD has come from 
the families  of veterans  of the Gulf War [176, 177].  After veterans  with  Gulf  War  Illness 
returned to the home, their children subsequently became symptomatic, and these children were 
often diagnosed with ASD [178].  Symptomatic children with ASD were infected with the same 
Mycoplasma  species,  M.  fermentans,  that  was  found  in  the  veterans  and  their  symptomatic 
family members, and this was not seen in aged-matched control subjects or in military families 
without GWI.  In these families some non-symptomatic family members did have mycoplasmal 
infections (~10%), but this was not significantly different from the incidence of mycoplasmal 
infections in healthy control subjects [177, 178]. 
Non-military families were also examined for systemic mycoplasmal infections [26].  In the 
ASD cases a majority were positive for mycoplasmal infections.  In contrast to the children from 
military families who for the most part had only  M. fermentans, the civilian children tested 
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patients showed evidence of Mycoplasma infections compared to age-matched control subjects 
(Odds  Ratio=13.8,  p<0.001).    ASD  patients  were  also  examined  for  C.  pneumoniae  (8.3% 
positive, Odds Ratio=5.6, p<0.01) and HHV-6 (29.2% positive, Odds Ratio=4.5, p<0.01). The 
results indicated that a large subset of ASD patients have bacterial and/or viral infections (Odds 
Ratio=16.5, p<0.001) [26].
 
In addition to Mycoplasma infections, many ASD patients have B. burgdorferi infections 
[179].  Various studies revealed that 22-30% of ASD patients have Borrelia infections [169].  
The  incidence  of  Borrelia  infections  in  ASD  patients  may  be  related  to  Lyme  disease 
distribution, and other Lyme-associated infections, such as Bartonella, Babesia, Ehrlichia, may 
also be present in ASD patients [169]. 
  Mitochondrial dysfunction is a common finding in ASD [180, 181].  Many mitochondrial 
biomarkers were significantly different between ASD patients and controls, and some markers 
correlated  with  ASD  signs  and  symptoms  severity  [181].    Because  of  the  similarities  in 
symptoms, mitochondrial dysfunction in ASD patients may be related to non-ASD mitochondrial 
disease  [181].    In  addition,  there  was  also  an  association  between  ASD  and  immune 
dysregulation and inflammation, oxidative stress, and toxicant exposures [182].  Palmieri and 
Persico have proposed that mitochondrial dysfunction in ASD is a down-stream affect, since it 
cannot be directly linked to many genetic or genomic defects found in ASD patients.  Thus 
mitochondrial dysfunction in ASD may be due to the consequences of dysreactive immunity or 
altered calcium signaling [183]. 
 
Fatiguing Illnesses 
Fatigue is usually understood as a subjective loss of energy and inability to perform even simple 
tasks without exertion.  It is the most common complaint of patients seeking general medical 
care  [184, 185].  Fatigue occurs naturally during aging, and it is also an important secondary 
condition in many clinical illnesses, including respiratory, coronary, musculoskeletal, and bowel 
conditions as well as infections [184-186].  
 
Chronic Fatigue Syndrome (CFS) 
Chronic fatigue lasting more than 6 months that is not reversed by normal sleep along with other 
signs/symptoms (including neurophysiological) usually indicates CFS [187, 188].  CFS patients 
also  display  immune  abnormalities,  inflammation,  autonomic  dysfunction  and  impaired 
functioning of the hypothalamic-pituitary-adrenal axis [189-191].  This results in alternations in 
immune cells, such as natural killer cells, and release of pro-inflammatory cytokines [191-195].  
Most  CFS  patients  have  multiple  chronic  bacterial  and  viral  infections  [196-200].    A 
common finding was systemic Mycoplasma species [197, 200].  For example, when patients 
were examined for evidence of any multiple, systemic bacterial and viral infections, the odds 
ratio for this was found to be 18 (CI 95% 8.5-37.9, p<0.001) [197].  In addition to Mycoplasma 
species (OR=13.8, CI 95% 5.8-32.9, p<0.001), co-infections with C. pneumoniae (OR=8.6, CI 
95% 1.0-71.1, p<0.01) and HHV-6 (OR=4.5, CI 95% 2.0-10.2, p<0.001) were also found [197].  
The  presence  of  these  infections  was  also  related  to  the  number  and  severity  of  signs  and 
symptoms [201].  Similarly, Vojdani  et al.  also found  Mycoplasma species in a majority of 
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be important, because when European CFS patients were examined for various  Mycoplasma 
species, the most common species found was M. hominis [203], whereas in North America the 
most common species found was M. pneumoniae [197, 201].  
CFS patients are also often found to be infected with B. burgdorferi [204], C. pneumoniae 
[197,  201,  205],  cytomegalovirus  [206],  B19  parvovirus  [207]  and  HHV-6  [197,  201,  208].  
However, not all studies on infections in CFS patients have been accurate. A recent finding of a 
retrovirus (XMRV) in CFS patients has been proven to be an artifact [209]. 
As with other diseases that show high rates of chronic infections, CFS patients are also 
dysfunctional  in  their  mitochondria  [210,  211].    Studies  have  shown  deficiencies  in  ATP 
production [210, 211] and reduced mitochondrial inner membrane potential [212] in white blood 
cells from CFS patients. Myhill et al. have proposed that CFS patients have basically two types 
of mitochondrial impairments: substrate or co-factor deficiencies or defects caused by exogenous 
or endogenous mitochondrial toxic factors [213].  Intracellular infections are likely the most 
common cause of the latter type of mitochondrial dysfunction. 
 
Fibromyalgia (FM) 
FM has many signs and symptoms in common with CFS, such as debilitating fatigue, mood and 
cognitive changes and sleep disturbances, but FM patients also present with widespread pain and 
abnormal  pain  processing  [214,  215].    Among  the  risk  factors  for  FM  include  genetic 
predisposition, obesity, allergies, toxins, autoimmune responses, physical trauma and chronic 
infections [215, 216].  Up to 70% of FM patients are also diagnosed with CFS  [217]. 
As with CFS, a high incidence of chronic bacterial and viral infections have been found in 
FM  patients  [2, 215].  Among the most commonly found infections  are due to  intracellular 
bacteria, such as Mycoplasma, Chlamydia, Brucella and Borrelia (reviewed in [215]).  Similarly, 
viral  infections  have  also  been  noted,  such  as  cytomegalovirus,  enteroviruses  and  HHV-6 
(reviewed in [215]).  These infections are often found at the same or higher incidence rates as 
those found in CFS patients. 
Autoantibodies  are  routinely  found  in  FM  patients.  One  study  reported  thyroid 
autoantibodies in 41% of FM patients versus 15% of controls [218], and another report indicated 
34.4% of FM patients were positive versus 18.8% in controls (p=0.025) [219]. Autoantibodies to 
serotonin were also identified in 74% of 50 patients with FM compared with 6% of 32 controls 
[220]. 
As with CFS, FM patients show dysfunctional mitochondria [221, 222].  Excess oxidative 
stress  was  indicated by lipid  peroxidation  in  blood  mononuclear cells  and plasma  from  FM 
patients  [222].    In  addition,  reduced  inner  mitochondrial  membrane  potential  initiating 
mitophagy and reductions in functional mitochondria were also found, suggesting that oxidative 
stress and increased mitophagy may play a role in the pathophysiology of FM [222].  Similar to 
CFS  patients,  FM  patients  also  show  reduced  production  of  ATP  but  there  were  also  some 
differences between CFS and FM patients.  In FM patients lower levels of citrate synthase and 
other enzymes and lower amounts of mtDNA were found compared to CFS patients [223]. 
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Consequences of Mitochondrial Dysfunction  
Mitochondrial dysfunction arises from an inadequate number of mitochondria within cells, an 
inability to provide necessary substrates and cofactors to mitochondria, and dysfunction in their 
electron  transport  or  ATP  synthesis  machinery.    The  number  and  functional  status  of 
mitochondria in a cell can be changed by the fusion of partially dysfunctional mitochondria and 
mixing of undamaged components to improve overall function (mitophagy), the generation of 
entirely new mitochondria (fission), and the removal and complete degradation of dysfunctional 
mitochondria (autophagy) [224].  These events are controlled by complex cellular processes that 
sense  the  deterioration  of  mitochondria,  such  as  the  loss  of  inner  mitochondrial  membrane 
potential
 or the activation of certain transcription pathways [225]. 
The ability of mitochondria to produce high-energy molecules like ATP is directly related to 
the  ability  of  the  electron  transport  chain  to  convert  the  energy  of  metabolites  to  transfer 
electrons to the electron transport chain from NADH and eventually to molecular oxygen while 
pumping protons from the mitochondrial matrix across the inner mitochondrial membrane to the 
intermembrane  space  [225].    This  creates  a  transmembrane  proton  gradient  (∆p)  and 
elect m) across the mitochondrial inner membrane that is used by ATP 
synthase to generate ATP [226].  
As a consequence of the electron transport process highly reactive free radicals, such as 
Reactive Oxygen Species (ROS), are produced as a byproduct of oxidative phosphorylation. The 
main cellular sources of ROS and related Reactive Nitrogen Species (RNS) are mitochondria, 
and when produced in excess over cellular antioxidant systems these free radicals can damage 
cellular lipids, proteins and DNA [227-229].  There are cellular mechanisms to neutralize excess 
ROS/RNS, such as dismutase enzymes and antioxidants [230].  Another mechanism to control 
the amount of excess ROS is by a controlled leak of protons back across the inner mitochondrial 
membrane via uncoupling proteins that allow protons to flow against the proton gradient [226, 
231].  
Excess  oxygen  consumption,  controlled  mitochondrial  proton  leak  and  resulting  ROS 
production can result in inappropriate damage to mitochondrial membrane lipids [228, 232], such 
as the very ROS/RNS-sensitive inner mitochondrial phospholipid cardiolipin [232].  Oxidative 
damage of inner mitochondrial membrane cardiolipin and other membrane phospholipids can 
result in increased proton and ion leakage across the inner membrane and partial loss of the 
electrochemical gradient.  Cardiolipin is an important component of the electron transport chain, 
providing stability for the cytochrome/enzyme complexes in the inner mitochondrial membrane 
[232, 233]. If damaged by ROS/RNS, oxidized cardiolipin results in loss of electron transport 
function [233]. 
Antioxidant defenses usually maintain ROS/RNS levels at concentrations that do not result 
in oxidation of cellular molecules or stimulate adverse events like carcinogenesis [234, 235].  
Endogenous cellular antioxidant defenses are essentual for protecting cellular molecules from 
oxidative damage and are mediated by proteins, such as glutathione peroxidase, catalase and 
superoxide dismutase, among others [236, 237].  There are also low molecular weight dietary 
antioxidants that can modify anti-oxidant oxidant balance [238-240].  Some of these dietary 
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oxidative molecules down to physiological levels that can be maintained by endogenous cellular 
antioxidant systems [241]. 
 
Supplements for Fatigue and and Mitochondrial Dysfunction 
Although mild fatigue can be related to psychological disturbances, moderate to severe fatigue is 
almost always related to loss of mitochondrial function and diminished production of ATP [211, 
212]. A number of natural supplements have been used to treat non-psychological fatigue and 
mitochondrial  dysfunction  [6,  242-244].    These  include  supplements  containing  vitamins, 
minerals, antioxidants, metabolites, enzyme inhibitors and cofactors, mitochondrial transporters, 
herbs and membrane phospholipids (Table 1) [6, 243].  Although several natural supplements 
have  been  used  to  reduce  fatigue  and  improve  mitochondrial  function,  few  are  considered 
effective [245].  Among the most useful supplements are the following: 
 
Table 1. Relative Incidence of Some Infectious Agents in Patients with Chronic Disease* 
______________________________________________________________ 
 
      ALS  MS  AD  PD  ASD  CSF  FM 
______________________________________________________________ 
Borrelia spp    ++  ++  ++  +  ++  ++  ++ 
Chlamyda spp.    +  ++++  +++  ++  ++  ++  ++ 
Mycoplasma spp.   +++++ +++  ++  ++  +++++ +++++ +++++ 
Brucella spp.    +        +++  ++  ++ 
Cytomegalovirus     ++  +    ++  +  + 
HSV -1      +  +++  +++    ++ 
HSV-2        +      + 
HHV-6      ++  +++  ++    +++  +++  +++ 
Heliobacter spp.        ++  +++  +  +  + 
Other virus/bacteria  +++  +++  ++  ++  + ++  ++  +++ 
_____________________________________________________________ 
 
*Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis;  
ASD, autism spectrum disorders; CFS, chronic fatigue syndrome; FM, fibromyalgia; 
HSV, herpes simplex virus; HHV, human herpes virus; MS, multiple sclerosis; 
PD, Parkinson’s disease 
Incidence (above controls): -, 0-1%; +, 1-5%; ++, 6-15%; +++, 16-25%; ++++, 26-50%; +++++, 51-90% 
 
L-Carnitine (LC) 
LC (3-hydroxy-4--trimethylaminobutyrate) is a naturally occurring fatty acid transporter found 
in  all  species  of  mammals  that  is  directly  involved  in  the  transport  of  fatty  acids  into  the 
mitochondrial matrix for subsequent -oxidation [246, 247].  It also functions in the removal of 
excess fatty acyl groups from the body and in the modulation of intracellular Coenzyme A (CoA) 
homeostatasis [246, 247].   Due to its importance in fatty acid oxidation and CoA and acyl-CoA 
homeostatasis, LC is usually maintained within relatively narrow concentration limits.  It is an 
important  dietary  supplement  for  maintaining  optimal  LC  concentration  within  cells  [246].   
Thus  LC  deficiency  disorders  are  associated  with  reduced  mitochondrial  function,  insulin 
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The importance of LC in mitochondrial health has spurred the use of LC supplements to 
potentially improve mitochondrial function and physical performance [250]. The justification is 
that increased reliance on fat as the principle substrate for energy production during extreme 
exercise should reduce the need for carbohydrates and delay the depletion of carbohydrate stores. 
This should increase overall energy production and reduce exercise-induced fatigue. Increased 
reliance on lipids  requires  increased levels  of  LC  to  transport fatty  acids  into mitochondria.  
However, increasing intake of oral LC, even for a few weeks prior to extreme exercise, did not 
increase  skeletal  muscle  carnitine  content,  and  therefore  it  is  unlikely  that  increasing  LC 
supplementation alters muscle metabolism during extreme exercise [251]. 
LC  supplementation  has  been  used  in  disorders  that  are  characterized  by  low  LC 
concentrations  or  impaired  fatty  acid  oxidation,  such  as  diabetes,  sepsis,  renal  disease  and 
cardiomyopathy  [252].    For  example,  in  patients  with  congestive  heart  failure  propionyl-LC 
supplementation  resulted  in  increased  peak  heart  rate  (increased  mean  by  12%),  exercise 
capacity (increased mean by 21%) and peak oxygen consumption (increased mean by 45%) in 
the treatment group [253]. 
Since the rate of mitochondrial oxidative phosphorylation naturally declines with age an 
important  anti-aging  use  of  LC  has  been  to  increase  the  rate  of  mitochondrial  oxidative 
phosphorylation  in  aged  populations.  Feeding  old  rats  acetyl-LC  was  found  to  reverse  age-
related decreases in LC levels while increasing fatty acid metabolism.  It also reversed the age-
related decline in cellular glutathione levels and improved muscle mitochondrial complex IV 
activity [251]. 
Dietary supplementation with LC and its various derivatives (up to 2 g per day)
 is a safe and 
potentially  useful  method  to  increase  mitochondrial  function  [254].    Multiple  clinical  trials 
demonstrating  its  effectiveness  in  age-related  chronic  illnesses  other  than  diabetes  and 
cardiovascular diseases have not been conducted.  One exception was a randomized, controlled 
clinical trial on 70 elderly subjects who were treated with LC for 6 months.  At the beginning of 
the trial the aged subjects were generally found to have muscle weakness, decreasing mental 
health, impaired mobility and poor endurance.  By the end of the study the treated group showed 
significant improvements in physical fatigue, mental fatigue and fatigue severity.  They also 
displayed  reductions  in  total  fat  mass, increased muscle mass and  an increased capacity  for 
physical and cognitive activity through reduced fatigue and improved cognitive function [255].  
Other clinical trials on alcoholism, hepatic encephalopathy, coronary heart diseases, Peyronie’s 
disease, cerebral ischemia and infertility indicate that supplementation with LC can have positive 
effects (reviewed in [254]). 
 
Alpha-Lipoic Acid  (ALA) 
ALA  (1,2-dithiolane-3-pentanoic  acid)  is  a  potent  antioxidant,  transition  metal  ion  chelator, 
redox transcription regulator and anti-inflammatory agent [257].  ALA acts as a critical cofactor 
-ketoacid  dehydrogenases,  and  it  is  important  molecule  in  mitochondrial 
oxidative decarboxylation [257, 258].  Clinically ALA has been used as an oral supplement in 
the treatment of complications associated with diabetes mellitus, and it has been shown to bring 
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health  [245].  These  effects  have  been  attributed  mainly  to  ALA  having  signal  transduction 
effects on gene regulation and glucose uptake and metabolism [259]. 
During aging and in many chronic diseases certain sphingolipids, especially ceramides and 
in  particular  short-chain  ceramides,  accumulate  in  mitochondria  due  to  hydrolysis  of 
sphingomyelin by sphingomyelinase.  Eventually this retards electron transport activity [260, 
261].  Ceramide accumulation in mitochondria is especially damaging in cardiac tissue, so in 
eramide levels in the vascular endothelial cells of 
cardiac  muscle  by  inhibiting  sphingomyelinase  activity.    This  resulted  in  restoration  of 
mitochondrial glutathione levels and increasing electron transport function [262]. 
As previously discussed, in diabetes ALA has been used to reduce diabetic complications, 
such as sensorimotor polyneuropathies [263].   A blinded study demonstrated its clinical utility 
-Lipoic acid (but not nerve 
conduction attributes) [264]. The long-term use of ALA has proven to be safe in diabetic patients 
[264]. 
Given as  an oral supplement ALA is  rarely present in tissues above micromolar levels; 
therefore, it is unlikely to be an important cellular antioxidant [258].  However, an important 
property of ALA is its ability to increase cellular glutathione levels by regulating glutathione 
synthesis  and  thus  indirectly  reducing  oxidative  stress  [252].    ALA  can  also  modify  the 
regulation of nuclear transcription factor NF-
transcriptional  effects,  resulting  in  the  reduction  of  free  radical  and  cytotoxic  cytokine 
production [265].   As a transition metal chelater ALA can remove excess copper, iron and other 
metals that are involved in chronic diseases, such as hemochromatosis, end-stage renal failure, 
AD and PD, and it is a potential therapeutic agent to prevent or mitigate heavy metal poisoning 
[256]. 
ALA has  been shown to improve cognitive function along  with  mitochondrial function, 
suggesting a link between oxidative damage to mitochondria and congnition [266].  ALA has not 
been used in clinical trials on chronic fatigue, but its widespread use as a safe supplement (at 
doses of 200-600 mg/day)
 to support mitochondrial function and reduce oxidative stress has 
justified its incorporation into various anti-aging and mitochondrial support supplements [264, 
265]. 
 
Coenzyme Q10 (CoQ10) 
Ubiquinone  or  CoQ10  is  a  key  mitochondrial  cofactor  and  component  of  the  mitochondrial 
electron transport chain and one of the most widely used natural supplements [243, 267].  It is 
also a strong antioxidant in its reduced form, and it can modify the expression of certain genes 
involved in cell signaling, metabolism and transport [267, 268].  The most important role of 
CoQ10  is  its  involvement  in  the  transfer  of  electrons  along  the  multiple  complexes  of  the 
mitochondrial electron transport chain [267, 269].  It has been used in doses up to 1,200 mg per 
day, but most studies used lower doses [267]. 
CoQ10 is an essential component of the mitochondrial oxidative phosphorylation system, 
thus  its  supplementation  in  patients  with  reduced  CoQ10  levels  should  result  in  increased 
mitochondrial energy production and reduced fatigue [267, 269].  A systematic review of the 
literature on the effects of CoQ10 on adaptive physical exercise, hypertension and heart failure Functional Foods in Health and Disease 2014; 4(1):23-65                                                                    Page 40 of 65 
 
revealed that most published studies showed modest improvements in exercise capacity in the 
subjects given oral CoQ10 [270].  In addition, in eight publications on the effects of CoQ10 on 
hypertension there was a mean decrease in systolic (-16 mm Hg) and diastolic (-10 mm Hg) 
blood pressure.  In nine randomized trials on the use of CoQ10 in heart failure patients there 
were non-significant trends towards increased injection fraction and reduced mortality [270].  
Rosenfeldt et al.
 performed their own three-month randomized, placebo-controlled trial on the 
effects of oral CoQ10 in patients with heart failure [270].  They found that in the test arm but not 
in the control arm patients showed significant improvements in symptoms and a trend towards 
improvements in mean exercise times [270]. 
As mentioned above, the anti-fatigue effects of oral CoQ10 during physical exercise have 
been examined in a blinded, cross-over trial [271].   Healthy subjects received CoQ10 or placebo 
for eight days, and their performance was evaluated at fixed workloads on a bicycle ergometer 
twice for two hr with a four hr rest in-between [271]. The subjects on CoQ10 were able to 
achieve higher work outputs, they reported less fatigue, and their need for a recovery period was 
alleviated compared to the placebo group [271].  This study indicated that CoQ10 is a useful 
supplement to improve fatigue and performance. 
In patients with various diagnoses, such as neurodegenerative disease, CoQ10 has been used 
to reduce symptoms and delay progression [267, 269].  In AD models CoQ10 administration 
significantly delayed brain atrophy and typical -amyloid plaque formation [272, 273].  In a 
randomized, placebo-controlled clinical trial on Alzheimer’s patients that took an oral mixture of 
CoQ10, vitamins C and E and ALA in the test arm showed significant reductions in oxidative 
stress markers but failed to show significant changes in cerebrospinal fluid markers related to -
amyloid or tau pathology [273].  PD patients generally show increased oxidized-to-total CoQ10 
ratios as well as significant increases in markers of oxidative damage in the cerebrospinal fluid, 
but  this  can be partially reversed with  CoQ10 supplementation [274].  In patients  with  early 
Huntington’s disease CoQ10 administration for 30 months  slowed the usual decline in  total 
functional capacity, but these differences did not reach statistical significance [275].  In contrast, 
in  a multi-center placebo-controlled phase  II trial  with  amyotrophic lateral  sclerosis  patients 
CoQ10 did not significantly modify functional decline over a nine-month period [276],
 and in 
genetic-based mitochondrial diseases CoQ10 plus several vitamins was shown to be ineffective 
[277].  
 
Reduced Nicotinamide Adenine Dinucleotide (NADH) 
NADH is a cellular redox cofactor in over 200 redox reactions and serves as substrate for certain 
enzymes [278, 279].   Cells have a universal requirement for NADH, and its deficiency results in 
a  condition  called  pellagra,  which  is  characterized  by  dermatitis,  diarrhea,  dementia  and 
eventually leads to death [279].  In the mitochondria NADH delivers electrons from lipid and 
other metabolite hydrolysis to the electron transport chain, but in its reduced form NADH can 
also act as a strong antioxidant [278, 279].   
Historically dietary NADH supplementation has been via NADH precursors, such as niacin, 
nicotinic acid or nicotinamide, but recently microcarriers have been used to stabilize oral NADH 
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than  using  large  oral  doses  of  uncomplexed  NADH,  which  are  prone  to  oxidation  and 
degradation and are generally considered ineffective [280]. 
In  many  chronic  diseases  oxidative  damage  is  extensive,  and  various  mitochondrial 
antioxidants have been used to treat disease and delay progression [4-6, 243, 281-284].  Nowhere 
has this been more apparent than in neurodegenerative diseases [4, 5, 84, 86, 134, 239].  For 
example,  in  AD  stabilized  oral  NADH  has  been  used  to  improve  cognitive  functioning  and 
dementia [278]; however, in another clinical trial there was no evidence of improvements in 
cognition or dementia using oral NADH [280].  In a controlled clinical trial AD patients were 
given stabilized NADH or placebo for six months, and it was found that the test group had 
significantly  better  performance  scores  than  the  placebo  group  (verbal  fluency,  visual 
construction  and  a  trend  toward  increased  performance  on  abstract  verbal  reasoning)  [285].  
However, there was no evidence of better performance using other measures (attention, memory) 
or on scores of dementia severity [285].   
Stabilized oral NADH has also been used to reduce the symptoms of PD.  In a preliminary 
open label clinical trial the effects of IV and oral NADH in over 800 Parkinson disease patients 
19.3% of patients showed 30-50% improvement in disability, 58.8% had moderate (10-30%) 
improvement, and 21.8% did not respond to the therapy (p<0.01) [286].  Younger patients with a 
shorter duration of disease responded better and showed more significant improvements than 
older  patients  and  patients  with  a  longer  duration  of  disease.    The  oral  form  was  found  to 
comparable to IV NADH in its effects [286].  However, when this type of trial was repeated 
statistically significant improvements in PD Rating scores were not found in patients treated with 
NADH, and diferences were also not found in CSF clinical markers associated with PD severity 
[287]. 
Oral NADH has also been used in a stabilized form to reduce symptoms in patients with 
chronic fatigue.  One such study on CFS patients used stabilized, oral NADH or placebo for four 
weeks  in  a cross-over trial [288].  Eight  of 26 patients  (30.7%) responded positively to  the 
microencapsulated  NADH  compared  with  2  of  26  (8%)  in  the  placebo  arm  (p<0.05)  [288].  
There was clearly an effect but only in a subset of patients in the trial.  These results were not 
considered significant by Colquhoun and Senn [289].  A comparison of oral, stabilized NADH to 
psychological/nutritional therapy in 31 chronic fatigue syndrome patients revealed that stabilized 
NADH alone reduced fatigue in the first 4 months of a 12-month trial.  After the first 4 months, 
however, symptom scores were similar in the NADH and the psychological/nutritional arms of 
the trial [290].  In another study stabilized NADH was given orally for two months to treat CFS 
patients with extensive fatigue [291].  Alegre et al. found in decreases in anxiety and maximum 
heart rate after a stress test, but there were little or no differences found in the functional impact 
of fatigue, quality of life, sleep quality, exercise capacity, or functional  reserve [291].  The 
stabilized NADH alone has shown mixed results in various diseases and disorders, and not every 
patient responded to the oral, stabilized supplement [6]. 
 
Lipid Replacement Theapy (LRT) 
The  dietary  replacement  of  cellular  membrane  phospholipids  (LRT)  using  food-derived 
glyerolphosholipids to remove damaged, mainly oxidized, membrane lipids in mitochondria and 
other  cellular  organelles  has  proved  very  effective  at  increasing  mitochondrial  function  and Functional Foods in Health and Disease 2014; 4(1):23-65                                                                    Page 42 of 65 
 
reducing  fatigue  [6,  7,  212,  244].
   To  some  degree  antioxidant  supplements  can  reduce 
ROS/RNS  levels  and  prevent  some  mitochondrial  membrane  phospholipid  oxidation,  but 
antioxidants alone cannot repair the damage already done to cells, and in particular, to their 
mitochondrial inner membranes [7, 244].
 
The use of oral membrane phospholipids plus antioxidants in doses ranging from 500-2,000 
mg per day has been effective in the treatment of various clinical conditions, such as CFS and 
other  fatiguing  illnesses  (Table  2)  [6,  7,  136,  212,  292,  293].
    LRT  results  in  the  actual 
replacement of damaged membrane phospholipids with undamaged (unoxidized) lipids to ensure 
proper function of cellular and especially mitochondrial membranes.  In these studies fatigue was 
monitored by use of the Piper Fatigue Scale (PFS) to measure clinical fatigue and quality of life 
[294].   
 
Table 2. A partial list of ingredients/agents or supplements that have been used  
or suggested to treat mitochondrial dysfuction
1  
 
Category    Examples 
__________________________________________________ 
 
Vitamins    Vitamins C, D and E, Thiamine, Riboflavin 
Minerals    Magnesium, Calcium, Phosphate 
Lipids    Membrane Phospholipids, Unsaturated Fatty Acids 
Metabolites   Creatine, Pyruvate 
Cofactors    CoQ10,Lipoic acid, NADH, nicotinic acid 
Transporters  L-Carnitine, Membrane Phospholipids 
Antioxidants  CoQ10, -Lipoic acid, NADH, Glutathione 
Enzyme inhibitors  -Lipoic acid, Dichloroacetate 
Herbs    Curcimin, Schisandrin 
_________________________________________________________ 
1 Modified from Kerr [243] and Nicolson [6] 
 
In a subsequent cross-over study the effects of LRT on fatigue and mitochondrial function 
were  monitored  in  patients  with  moderate  to  severe  chronic  fatigue  [212].  There  was  good 
correspondence  between  reductions  in  fatigue  and  gains  in  mitochondrial  function.    After  8 
weeks of LRT with NTFactor, mitochondrial function was significantly improved, and after 12 
weeks  of  NTFactor  supplementation,  fatigue  was  decreased  by  35.5%  (p<0.001),  and 
mitochondrial function was found to be similar to that found in young healthy adults (26.8% 
increase, p<0.0001) [212]. After 12 weeks of supplement use, subjects were placed on placebo 
for an additional 12 weeks, and their fatigue and mitochondrial function were again measured.  
After  the  placebo  period,  fatigue  and  mitochondrial  function  were  intermediate  between  the 
initial values and those found after 8 or 12 weeks on the supplement, indicating that continued 
supplementation is required to show improvements in mitochondrial function and maintain lower 
fatigue scores [212].   
Similar  findings  on  fatigue  reduction  were  observed  in  chronic  fatigue  syndrome  and 
fibromyalgia syndrome patients given oral membrane phospholipids (NT Factor) [293]. Using a 
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moderate chronic fatigue resulted in a 36.8% reduction in fatigue within one week [295] (Table 
3). 
 
Table 3.  Effects of Dietary LRT Supplement NTFactor
® on Piper Fatigue Scores.
1 
______________________________________________________________________________ 
           Av      Time    Piper Fatigue Score
2 
Subjects/patients    n   age  on LRT  Fatigue Reduction (%)    Reference 
______________________________________________________________________________ 
 
Chronic fatigue
3    34  50.3    8 wks   40.5**             Ellithorpe et al. [319] 
 
Aging, chronic fatigue
4  20  68.9  12 wks   35.5*           Agadjanyan et al. [212] 
   
CFS (and/or FM)
3    15  44.8    8 wks   43.1*    Nicolson & Ellithorpe [293] 
 
Obesity, fatigue
5    35  42   8 wks   24*              Ellithorpe et al. [318] 
 
Aging, chronic fatigue
6  67  57.3    1 wk    36.8*      Nicolson et al. [295]  
 
CFS, others
7      58  55.0    8 wk    30.7*      Nicolson et al. [302] 
______________________________________________________________________________ 
 
1Modified from Nicolson and Settineri [7] 
2From Piper et al. [294] 
3Propax
TM with NT Factor
® 
4NT Factor
® 
5Healthy Curb
TM with NT Factor
® 
6Advanced Physician’s Formula
TM with NT Factor
® 
7 ATP Fuel
® with NTFactor
®, CoQ10, NADH, LC, -keto glutaric acid 
**P<0.0001,  *P<0.001 compared to without NT Factor
® 
______________________________________________________________________________ 
 
Vitamins and Minerals 
Vitamins, minerals and other small molecules fall into the category of micronutrients.  They are 
essential in the support of mitochondrial function by providing antioxidants, cofactors, metal 
ions, salts, and other molecules that are essential in supporting the functions of mitochondrial 
enzymes,  electron  transport  systems,  mtDNA  replication,  fat  and  sugar  metabolism,  protein 
synthesis and proper antioxidant balance [296-298].  Vitamins, such as B (multiple), D, E, C, and 
ions, such as iron, magnesium, manganese, zinc, among other small molecules, are important n 
this regard, and up to one-half of the aging North American population is deficient in these 
vitamins, minerals and other micronutrients [299]. 
The use of micronutrients in helping to restore and/or maintain mitochondrial function has 
proven useful in consert with other treatment modialties [296, 298, 300].  Although there are few 
clinical trials in the literature that demonstrate the usefulness and utility of supplementation with 
only vitamins, minerals, antioxidants and other micronutrients alone in supporting mitochondrial 
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oral doses of vitamins, minerals, antioxidants and other micronutrients to maintain mitochondrial 
energy functions [296. 300-302].  However, their sole use in the treatment of mitochondrial 
diseases has proved disappointing [277].  But it is reassuring to find that many commercial 
mitochondrial supplements contain adequate amounts of these important molecules (for example 
[282,  292,  295,  302]).    Thus  in  addition  to  vitamins,  minerals,  antioxidants  and  other 
micronutrients,  other  supplement  components  are  likely  required  for  significant  and  lasting 
effects on mitochondrial function.  
 
Combination Supplements to Restore Mitochondrial Function 
Oral supplements containing membrane phospholipids (NTFactor, 2,000 mg/day), CoQ10 (35 
mg/day), microencapsulated NADH (35 mg/day), LC (160 mg/day), -ketoglutaric acid (180 
mg/day) and other micronutrients have been combined into a dietary supplement (ATP Fuel
®) to 
treat fatigue and mitochondrial dysfunction [303]. This formulation was used in a study to treat 
long-term intractable fatigue in patients with a variety of diagnoses during a two-month trial.  
The 58 participants in the ATP Fuel trial had moderate to severe intractable fatigue for an 
average  >17 years and had been to an average of >15 practitioners without resolution of their 
fatigue.  The study included 30 patients with chronic fatigue syndrome, 17 with chronic Lyme 
disease; 16 with other fatiguing illnesses, including fibromyalgia syndrome and Gulf War illness; 
4 with autoimmune disease, including rheumatoid arthritis; 2 cancer; and 2 diabetes.   These 
patients had tried unsuccessfully many drugs and supplements (average >35) to reduce their 
fatigue without success [303]. 
Participants in the trial included chronic illness patients who took the combination LRT 
supplement (ATP Fuel
®) for 8 weeks, and their fatigue was scored monthly [303].  The Piper 
Fatigue  Score  (PFS)  is  a  validated  instrument  that  measures  four  dimensions  of  subjective 
fatigue: behavioral/severity, affective/ meaning, sensory, and cognitive/mood [294]. These were 
used to calculate the four subscale/dimensional scores and the total fatigue scores.
  In this study 
the long-term chronic illness patients with intractable fatigue had initial PFS mean total fatigue 
scores of 7.51 ± 0.29, and after 8 weeks of supplement the mean scores improved to 5.21 ± 0.28, 
or a 30.7% reduction in fatigue (p<0.0001) [303].   
The  PFS  fatigue  scores  can  be  further  dissected  into  four  subcategories:  (i) 
Behavior/Severity  subcategory,  which  deals  with  completing  tasks,  socializing,  engaging  in 
sexual activity and other activities, and intensity or degree of fatigue; (ii) Affective/Meaning 
subcategory, which determines whether the fatigue/tiredness is pleasant/unpleasant, whether the 
patient is agreeable/disagreeable, protective/destructive, or feels normal/abnormal; (iii) Sensory 
subcategory, which determines whether the patient is strong/weak, awake/sleepy, refreshed/tired, 
or energetic/unenergetic; and 
 (iv)
 Cognitive/Mood subcategory, which assesses whether a patient 
feels  relaxed/tense,  exhilarated/depressed,  able/unable  to  concentrate,  remember,  and  think 
clearly) [294].  All of these fatigue subcategories showed significant reductions by the end of the 
8-week  trial  (p<0.0001).  For  example,  there  was  a  30.7%  reduction  (p<0.0001)  in 
severity/behavior of fatigue, indicating that there was a significant reduction in the intensity of 
fatigue, and a significant increase in the ability to complete tasks, socialize, and engage in sexual 
and  other  activities.    Also,  there  was  also  a  28.0%  improvement  (p<0.0001)  in  mood  and 
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The  benefits  of  combining  various  natural  mitochondrial  support  components  into 
combination mitochondrial supplements should be obvious.  Separate supplements are no longer 
required,  and  the  individual  components  can  be  adjusted  in  dosage  to  provide  maximal 
effectiveness.  Also, with combined supplements patients who often have memory and other 
defects are more likely to be compliant than with the requirement of taking several separate 
supplements  on  a  daily  basis.    New  formulations  can  be  designed  to  replace  damaged 
mitochondrial components and also address particular protective needs, such as preconditioning 
to defend against oxidative stress, damage to ion channels and other needs [304].
 
 
Final Comments 
There  is  ample  evidence  that  intracellular  infections  are  linked  to  mitochondria  and 
mitochondrial dysfunction.  Mitochondria play essential roles in cellular homeostasis through 
control of cell death and as sentinels of cellular danger, such as oxidative stress, loss of essential 
growth and maintenance factors, physical damage and infection by foreign agents [305-307].  
They also orchestrate cellular adaptive danger responses to sustain cell survival, especially when 
infections threaten cellular systems [307, 308].  However, microorganisms have evolved with 
different strategies to evade or circumvent host mechanisms to identify, neutralize and degrade 
them [308-310]. 
During infection and cellular invasion by microorganisms coordination of multiple innate 
immune  signaling  pathways  occurs  through  different  pathogen-associated  molecular  pattern 
recognition receptors.  The recognition of foreign invaders (and other danger molecules) by these 
innate receptors (Patern Recognition Receptors) can initiate an intracellular signaling cascade 
that results in activation of anti-microbial mechanisms to clear the infection [311, 312].  
Mitochondria have emerged as critical regulators of innate immune responses to invading 
pathogens as well as other stressors [311-313].  They initiate immune signaling modulators that 
are tightly linked to mitochondrial energetics through intracellular danger-sensing multiprotein 
platforms  called  inflammasomes  [12,  313,  314].    Thus  mitochondria  operate  as  fundamental 
“hubs”  in  the  pathways  from  detection  of  intracellular  pathogens  to  adaptive  responses  that 
attempt to neutralize and eliminate pathogens as well as housing crucial signal transducers and 
providing a structural scaffold that is involved in regulating anti-microbial activities [305, 306].  
They  also  warn  the  host  with  danger  signals  by  providing  multiple  mitochondrial  damage 
products (DAMPS) that are recognized by the innate immune system, resulting in the stimulation 
of local or systemic immune responses [315]. 
Mitochondria are addionally implicated in pathways that result in the cellular destruction of 
pathogens  by  autophagy  through  specialized  autophagosomes  [304,  307].  When  pathogens 
damage cells beyond their ability to be repaired, mitochondria are also involved in initiating and 
removing  the  damaged  cells  by  apoptosis  [304,  316].    They  not  only  modulate  apoptosis 
triggered by terminal alternations in intracellular homeostasis, but they can also participate in 
apoptosis  stimulated  by  responses  to  extracellular  or  external  signals    [317,  318].    Thus 
mitochondria are intrinsically tied to cellular infections in a number of ways.  
Oral  mitochondrial  supplements  containing  various  mitochondrial  substrates,  cofactors, 
precursors,  components  and  modulators  have  proven  useful  in  maintaining  and  improving 
mitochondrial function in various chronic diseases.  In some examples cited in here this has Functional Foods in Health and Disease 2014; 4(1):23-65                                                                    Page 46 of 65 
 
resulted in reduction of specific illness signs and symptoms, improvements in quality of life and 
assistance  in  over-all  recovery.    Future  efforts  to  refine  and  improve  oral  mitochondrial 
supplements and apply them clinically should enhance our abilities to treat and care for chronic 
illness patients as well as improve quality of life for aging populations. 
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